Intravenous thrombolysis in acute ischaemic stroke: Optimising its use in routine clinical practice

CNS Drugs

Volumn 19, Issue 4, 2005, Pages 295-302

  Bravata, Dawn M ^a,b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT; PLACEBO;

BLEEDING; BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; FIBRINOLYTIC THERAPY; HUMAN; MENTAL COMPLIANCE; PRIORITY JOURNAL; REVIEW; STROKE;

AGED; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOLS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; THROMBOLYTIC THERAPY;

EID: 17844407412     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200519040-00002     Document Type: Review

References (34)

1. Warlow C. Epidemiology of stroke. Lancet 1998; 352 Suppl. 3: SIII1-4
2. Broderick J, Brott T, Kothari R, et al. The Greater Cincinnati/Northern Kentucky Stroke Study: preliminary first-ever and total incidence rates of stroke among blacks. Stroke 1998; 29: 415-21
3. Johnston S. Transient ischemic attack. NEJM 2002; 347 (21): 1687-92
4. Whisnant JP. Populations, Cohorts, and Clinical Trials. Oxford: Butterworth-Heinemann Ltd., 1993
5. Adams H, Brott T, Furlan A, et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischaemic stroke. Circulation 1996; 94(5): 1167-74
6. Adams Jr HP, Adams RJ, Brott T, et al. Guidelines for the early management of patients with ischaemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke 2003; 34 (4): 1056-83
7. Mori E, Yoneda Y, Tabuchi M, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992; 42 (5): 976-82
8. Yamaguchi T, on behalf of Japanese Thrombolysis Study Group. Intravenous tissue plasminogen activator in acute carotid artery territory stroke: a placebo controlled, double blind trial. In: del Zoppo G, Mori E, Hacke W, editors. Thrombolytic therapy in acute ischaemic stroke II. New York (NY): Springer Verlag, 1993: 59-65
9. Anonymous. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial-Italy (MAST-1) Group. Lancet 1995; 346 (8989): 1509-14
10. The Multicenter Acute Stroke Trial-Europe Study Group. Thrombolytic therapy with streptokinase in acute ischaemic stroke. N Engl J Med 1996; 335: 145-50
11. Donnan G, Davis S, Chambers B, et al. Streptokinase for acute ischaemic stroke with relationship to time of administration. JAMA 1996; 276: 961-6
12. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274 (13): 1017-25
13. Anonymous. Tissue plasminogen activator for acute ischaemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333 (24): 1581-7
14. Clark WM, Albers GW, Madden KP, et al. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study: Thromblytic Therapy in Acute Ischaemic Stroke Study Investigators. Stroke 2000; 31 (4): 811-6
15. Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (alteplase) for ischaemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischaemic Stroke. JAMA 1999; 282 (21): 2019-26
16. Albers GW, Bates VE, Clark WM, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000; 283 (9): 1145-50
17. Tanne D, Bates VE, Verro P, et al. Initial clinical experience with IV tissue plasminogen activator for acute ischaemic stroke: a multicenter survey. The t-PA Stroke Survey Group. Neurology 1999; 53 (2): 424-7
18. Grond M, Stenzel C, Schmulling S, et al. Early intravenous thrombolysis for acute ischaemic stroke in a community-based approach. Stroke 1998; 29: 1544-9
19. Trouillas P, Nighoghossian N, Derex L, et al. Thrombolysis with intravenous rtPA in a series of 100 cases of acute carotid territory stroke: determination of etiological, topographic, and radiological outcome factors. Stroke 1998; 29 (12): 2529-40
20. Wang DZ, Rose JA, Honings DS, et al. Treating acute stroke patients with intravenous tPA: the OSF stroke network experience. Stroke 2000; 31 (1): 77-81
21. Chiu D, Krieger D, Villar-Cordova C, et al. Intravenous tissue plasminogen activator for acute ischaemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. Stroke 1998; 29: 18-22
22. Koennecke HC, Nohr R, Leistner S, et al. Intravenous tPA for ischaemic stroke team performance over time, safety, and efficacy in a single-center, 2-year experience. Stroke 2001; 32 (5): 1074-8
23. Katzan I, Furlan A, Lloyd L, et al. Use of tissue-type plasminogen activator for acute ischaemic stroke: the Cleveland area experience. JAMA 2000; 283 (9): 1151-8
24. Lopez-Yunez AM, Bruno A, Williams LS, et al. Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage. Stroke 2001; 32 (1): 12-6
25. Bravata D, Kim N, Concato J, et al. Thrombolysis for acute stroke in routine clinical practice. Arch Intern Med 2002; 162 (17): 1994-2001
26. Buchan AM, Barber PA, Newcommon N, et al. Effectiveness of t-PA in acute ischaemic stroke: outcome relates to appropriateness. Neurology 2000; 54 (3): 679-84
27. Heuschmann PU, Berger K, Misselwitz B, et al. Frequency of thrombolytic therapy in patients with acute ischaemic stroke and the risk of in-hospital mortality: the German Stroke Registers Study Group. Stroke 2003; 34 (5): 1106-13
28. Lindsberg PJ, Soinne L, Roine RO, et al. Community-based thrombolytic therapy of acute ischaemic stroke in Helsinki. Stroke 2003; 34 (6): 1443-9
29. Collins DR, O'Neill D, McCormack PM. Potential for treatment with thrombolysis in an Irish stroke unit. Ir Med J 1999; 92 (1): 236-8
30. Johnston SC, Fung LH, Gillum LA, et al. Utilization of intravenous tissue-type plasminogen activator for ischaemic stroke at academic medical centers: the influence of ethnicity. Stroke 2001; 32 (5): 1061-8
31. Reed SD, Cramer SC, Blough DK, et al. Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischaemic stroke treated in community hospitals. Stroke 2001; 32 (8): 1832-40
32. Morgenstern LB, Bartholomew LK, Grotta JC, et al. Sustained benefit of a community and professional intervention to increase acute stroke therapy. Arch Intern Med 2003; 163 (18); 2198-202
33. Katzan IL, Hammer MD, Furlan AJ, et al. Quality improvement and tissue-type plasminogen activator for acute ischaemic stroke: a Cleveland update. Stroke 2003; 34 (3): 799-800
34. Lattimore SU, Chalela J, Davis L, et al. Impact of establishing a primary stroke center at a community hospital on the use of thrombolytic therapy: the NINDS Suburban Hospital Stroke Center experience. Stroke 2003; 34 (6): e55-7